Sometimes there is still hope for patients who have exhausted all treatment options. Medical treatments that are still being developed could provide them with the necessary health benefits. myTomorrows (mT) links patients to drugs that are in the clinical development phase. This sounds simpler than it is. mT is doing well. Every year, thousands of patients and doctors are helped with information about and access to medicines under development. At the same time you see that not everything works. mT developed three pilots to experiment with a new reimbursement system, including a pilot for early access to a gene therapy. All three pilots failed because several parties pulled out prematurely.

Access and affordability of new medicines is under pressure. Early access can contribute by improving the drug development process with the help of data collection and price agreements. The approach to COVID-19 has shown that early access plays an important role and all parties would do well to positively assess developments such as mT as forerunners of an improved system of drug development.